Hikma Pharmaceuticals (GB:HIK) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive audit tender process. As part of regulatory requirements, Hikma must rotate auditors every 20 years, and this decision awaits shareholder approval at the 2026 Annual General Meeting. Investors may find this continuity in auditing services a point of stability for the company’s financial oversight.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.